Objective:
To review recent developments in the US market for locally delivered steroid therapies for uveitis, including product discontinuations, relaunches, and label expansions, and their clinical implications.
Key Findings:
- Retisert will be discontinued in April 2026 due to manufacturing issues, impacting patients reliant on this treatment.
- Triesence has been relaunched with a significant price increase after a prolonged shortage, raising concerns about patient access.
- Yutiq and Iluvien have expanded indications for chronic noninfectious uveitis, providing alternative options for patients.
Interpretation:
The changes in the availability of local steroid therapies for uveitis necessitate careful consideration of alternative treatments, such as Yutiq and Iluvien, for patients affected by these discontinuations.
Limitations:
- The article does not provide data on patient outcomes following the transition to alternative therapies, which is crucial for assessing treatment efficacy.
- Potential impacts of increased costs on patient access to treatment are not discussed, which could affect treatment adherence.
Conclusion:
The landscape of local steroid treatments for uveitis is evolving, with significant implications for patient management and treatment options, necessitating a reassessment of therapeutic strategies.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
